Shenzhen Mindray Stock Hits Day Low at CNY 146 Amid Price Pressure

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. experienced a notable decline today, with the stock dropping by 3.01% on June 15, 2026. The stock reached an intraday low of CNY 146.00, reflecting ongoing challenges in its performance metrics. Over the past year, the company has faced significant headwinds, with a return of -38.26%, contrasting sharply with the China Shanghai Composite's gain of 21.31% during the same period. In terms of financial health, Shenzhen Mindray reported a net profit of CNY 5,395.49 million for the first nine months, marking a decline of 19.91%. The operating cash flow stands at CNY 10,041.18 million, the lowest recorded. Despite these challenges, the company maintains a return on equity of 20.40% and a price-to-book ratio of 4.31, indicating a potentially attractive valuation relative to its book value. The stock's performance over various time frames highlights a consistent underperformance compared to the broader market, with a year-to-date decline of 23.08% and a staggering 51.54% drop over the past three years. As the company navigates these trends, its large-cap status in the pharmaceuticals and biotechnology sector remains a focal point for market observers.